ESSA Pharma 2021 Corporate Presentation - EPI-7386 Prostate Cancer

ESSA Pharma is a clinical-stage biotech focused on developing first-in-class N-terminal domain inhibitors for prostate and hormone-driven cancers. The company is advancing EPI-7386 in Phase 1 studies for resistant metastatic castration-resistant prostate cancer and exploring combinations with antiandrogens and potential breast cancer indications.